--- title: "Rapport Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/294957159.md" datetime: "2026-08-05T11:18:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294957159.md) - [en](https://longbridge.com/en/news/294957159.md) - [zh-HK](https://longbridge.com/zh-HK/news/294957159.md) --- # Rapport Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -1.19, missing the estimate of USD -0.967. EBIT: As of FY2026 Q2, the actual value is USD -56.62 M. #### Net Loss Rapport Therapeutics, Inc. reported a net loss of - $56.6 million for the second quarter of 2026, compared to a net loss of - $26.7 million for the prior year period. #### Operating Expenses Research and Development (R&D) expenses were $51.4 million for the second quarter of 2026, an increase from $22.7 million in the prior year period, primarily due to costs related to clinical development and pipeline progression. Selling, General and Administrative (SG&A) expenses increased to $9.4 million for the second quarter of 2026, from $6.8 million in the prior year period, driven by business growth. #### Cash Position and Runway The company ended the second quarter of 2026 with $436.1 million in cash, cash equivalents, and short-term investments, excluding restricted cash, a decrease from $476.8 million as of March 31, 2026. This cash position is expected to fund operations into the second half of 2029. #### Balance Sheet Highlights (as of June 30, 2026, in thousands) - Cash and cash equivalents: $63,612 - Short-term investments: $372,465 - Restricted cash: $105 - Total current assets: $446,856 - Total assets: $458,982 - Total current liabilities: $28,424 - Total liabilities: $36,056 - Accumulated deficit: - $311,700 - Total stockholders’ equity: $422,926 #### Cash Flow Highlights (for the three months ended June 30, in thousands) - Net cash used in operating activities: - $41,455 in 2026, compared to - $25,070 in 2025. - Net cash provided by investing activities: $25,600 in 2026, compared to $22,596 in 2025. - Net cash provided by (used in) financing activities: $1,411 in 2026, compared to - $63 in 2025. #### Operational Metrics and Pipeline Updates The Phase 3 program for RAP-219 in focal onset seizures (FOS) has been initiated, with FOCUS 1 and FOCUS 2 trials actively enrolling patients. The China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for RAP-219 Phase 3 trials in FOS, and patient recruitment in China is expected to begin in Q4 2026. An open-label long-term safety trial for RAP-219 in FOS has been initiated, with initial data anticipated in Q4 2026. Follow-up Phase 2a data for RAP-219 in FOS showed sustained therapeutic levels and clinically meaningful improvements, including an 80% median reduction in long episodes and a 90% median reduction in clinical seizures in weeks 9-12. The estimated half-life of RAP-219 has increased to 22 days. The company is also preparing to initiate a Phase 3 trial of RAP-219 in primary generalized tonic-clonic seizures (PGTCS) in the first half of 2027. The Phase 2 trial for RAP-219 in bipolar mania continues to advance, with topline results expected in October 2026. IND-enabling activities for RAP-219’s long-acting injectable formulation are progressing, with initial Phase 1 pharmacokinetic data expected in 2027. The RAP-641 α6β4 nAChR program is moving towards IND submission. #### Outlook Rapport Therapeutics, Inc. expects to release topline results from its RAP-219 Phase 2 trial in bipolar mania in October 2026, and patient recruitment for RAP-219 Phase 3 trials in FOS in China is anticipated to commence in Q4 2026, alongside initial data from the open-label long-term safety trial. The company plans to initiate a Phase 3 trial for RAP-219 in PGTCS in the first half of 2027 and expects initial Phase 1 pharmacokinetic data for the long-acting injectable formulation in 2027. ### Related Stocks - [RAPP.US](https://longbridge.com/en/quote/RAPP.US.md) ## Related News & Research - [Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPP](https://longbridge.com/en/news/296325369.md) - [Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 million](https://longbridge.com/en/news/295706967.md) - [Rapport Therapeutics CEO Abraham Ceesay sells 2,210 shares worth $92,999.37](https://longbridge.com/en/news/294252845.md) - [Rapport Therapeutics CEO Abraham Ceesay sells 8,210 common shares worth $328,018](https://longbridge.com/en/news/292811724.md) - [Rapport Therapeutics CEO Abraham Ceesay disposes of common shares worth $327,031.55](https://longbridge.com/en/news/291456396.md)